Indeed, lenalidomide markedly increases NK cell activation and proliferation through the induction of IL-2 production by CD4 T cells in chronic lymphocytic leukemia (CLL) [46,47]. This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.